Is CFRX or MO a better dividend investment in 2026?

CFRX currently yields 4000.00% with a 5% 5-year dividend growth rate. MO yields 9.11% with 4.3% growth. The better choice depends on your goal: CFRX offers higher current income.

What is the dividend yield difference between CFRX and MO?

CFRX has a forward dividend yield of 4000.00% ($2.00/share annually). MO yields 9.11% ($4.08/share annually). The yield gap is 3990.89 percentage points.

Home › Compare › CFRX vs MO

CFRX vs MO: Dividend Comparison 2026

CFRX yields 4000.00% · MO yields 9.11%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CFRX wins by $7175340620755.84M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CFRX

● Live price

4000.00%

Share price

$0.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7175340620755.87M

Annual income

$6,839,006,593,197,835,000.00

Full CFRX calculator →

Altria Group Inc.

● Live price

9.11%

Share price

$44.80

Annual div

$4.08

5Y div CAGR

4.3%

Payout ratio

78%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.7K

Annual income

$4,052.72

Full MO calculator →

Portfolio growth — CFRX vs MO

📍 CFRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CFRX	MO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CFRX + MO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CFRX pays

MO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRX

Annual income on $10K today (after 15% tax)

$340,000.00/yr

After 10yr DRIP, annual income (after tax)

$5,813,155,604,218,160,000.00/yr

Annual income on $10K today (after 15% tax)

$774.11/yr

After 10yr DRIP, annual income (after tax)

$3,444.81/yr

At 15% tax rate, CFRX beats the other by $5,813,155,604,218,157,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRX + MO for your $10,000?

CFRX: 50%MO: 50%

100% MO50/50100% CFRX

Portfolio after 10yr

$3587670310377.95M

Annual income

$3,419,503,296,598,919,700.00/yr

Blended yield

95.31%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CFRX

Analyst Ratings

Strong

Buy

Hold

Consensus: Hold

Altman Z

-60.9

Piotroski

1/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$61.25

+36.7% upside vs current

Range: $47.00 — $68.00

Altman Z

3.2

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRX buys

MO buys

No recent congressional trades found for CFRX or MO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCFRXMO

Forward yield	4000.00% ✓	9.11%
Annual dividend / share	$2.00	$4.08 ✓
Payout ratio	50% ✓	78%
1-year div growth	0%	4.1% ✓
5-year div CAGR	0%	4.3% ✓
Portfolio after 10y	$7175340620755.87M ✓	$27.7K
Annual income after 10y	$6,839,006,593,197,835,000.00 ✓	$4,052.72
Total dividends collected	$7152397773804.84M ✓	$20.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Hold	Buy

Year-by-year: CFRX vs MO ($10,000, DRIP)

Year	CFRX Portfolio	CFRX Income/yr	MO Portfolio	MO Income/yr	Gap
1← crossover	$410,700	$400,000.00	$10,740	$949.88	+$400.0K → CFRX
2	$15,792,720	$15,353,271.03	$11,601	$1,086.84	+$15.78M → CFRX
3	$568,657,142	$551,758,931.89	$12,608	$1,250.75	+$568.64M → CFRX
4	$19,176,207,860	$18,567,744,718.20	$13,792	$1,448.20	+$19176.19M → CFRX
5	$605,696,028,890	$585,177,486,479.73	$15,190	$1,687.69	+$605696.01M → CFRX
6	$17,922,210,653,594	$17,274,115,902,681.27	$16,851	$1,980.28	+$17922210.64M → CFRX
7	$496,869,793,504,300	$477,693,028,104,954.00	$18,838	$2,340.48	+$496869793.49M → CFRX
8	$12,908,672,105,251,704	$12,377,021,426,202,104.00	$21,230	$2,787.44	+$12908672105.23M → CFRX
9	$314,330,866,876,668,540	$300,518,587,724,049,200.00	$24,130	$3,346.72	+$314330866876.64M → CFRX
10	$7,175,340,620,755,871,000	$6,839,006,593,197,835,000.00	$27,676	$4,052.72	+$7175340620755.84M → CFRX

CFRX vs MO: Complete Analysis 2026

CFRX — Stock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Full CFRX Calculator →

MO — Consumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →

📬

Get this CFRX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRX vs SCHD CFRX vs JEPI CFRX vs O CFRX vs KO CFRX vs MAIN CFRX vs PM CFRX vs BTI CFRX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.